Guy Novotny

Mr. Guy Novotny


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2015 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Open access
PDF file
MOMirwais Osmai
Mirwais Osmai
YOYama Osmai
Yama Osmai
CBClaus H. Bang‐Berthelsen
Claus H. Bang‐Berthelsen
EPEmil M. H. Pallesen
Emil M. H. Pallesen
AVAnna L. Vestergaard
Anna L. Vestergaard
TMThomas Mandrup-Poulsen
Thomas Mandrup-Poulsen
Summary: In the last decade, there has been an explosion in both the number of and knowledge about miRNAs associated with both type 1 and type 2 diabetes. Even though we are presently in the initial stages of understanding how this novel class of posttranscriptional regulators are involved in diabetes, recent studies have demonstrated that miRNAs are important regulators of the islet transcriptome, controlling apoptosis, differentiation and proliferation, as well as regulating unique islet and beta‐cell functions and pathways such as insulin expression, processing and secretion. Furthermore, a large number of miRNAs have been linked to diabetogenic processes induced by elevated levels of glucose, free fatty acids and inflammatory cytokines. Thus, miRNAs are novel therapeutic targets with the potential of protecting the beta‐cell, and there is proof of principle that miRNA antagonists, so‐called antagomirs, are effective in vivo for other disorders. miRNAs are exported out of cells in exosomes, raising the intriguing possibility of cell‐to‐cell communication between distant tissues via miRNAs and that miRNAs can be used as biomarkers of beta‐cell function, mass and survival. The purpose of this review is to provide a status on how miRNAs control beta‐cell function and viability in health and disease. Copyright © 2015 John Wiley & Sons, Ltd.

12 January 2007 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
GNGuy Novotny
Guy Novotny
SSS B Sonne
S B Sonne
JNJ E Nielsen
J E Nielsen
SJS P Jonstrup
S P Jonstrup
MHM A Hansen
M A Hansen
HLH Leffers
H Leffers
Translational repression of E2F1 mRNA in carcinoma in situ and normal testis correlates with expression of the miR-17-92 cluster

14 March 2012 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
GNGuy Novotny
Guy Novotny
KBKirstine Belling
Kirstine Belling
JBJesper Bertram Bramsen
Jesper Bertram Bramsen
JNJohn E Nielsen
John E Nielsen
JBJette Bork-Jensen
Jette Bork-Jensen
HLHenrik Leffers
Henrik Leffers
Testicular germ cell tumours, seminoma (SE) and non-seminoma (NS), of young adult men develop from a precursor cell, carcinomain situ(CIS), which resembles foetal gonocytes and retains embryonic pluripotency. We used microarrays to analyse microRNA (miRNA) expression in 12 human testis samples with CIS cells and compared it with miRNA expression profiles of normal adult testis, testis with Sertoli-cell-only that lacks germ cells, testis tumours (SE and embryonal carcinoma (EC), an undifferentiated component of NS) and foetal male and female gonads. Principal components analysis revealed distinct miRNA expression profiles characteristic for each of the different tissue types. We identified several miRNAs that were unique to testis with CIS cells, foetal gonads and testis tumours. These included miRNAs from the hsa-miR-371–373 and -302–367 clusters that have previously been reported in germ cell tumours and three miRNAs (hsa-miR-96, -141 and -200c) that were also expressed in human epididymis. We found several miRNAs that were upregulated in testis tumours: hsa-miR-9, -105 and -182–183–96 clusters were highly expressed in SE, while the hsa-miR-515–526 cluster was high in EC. We conclude that the miRNA expression profile changes during testis development and that the miRNA profile of adult testis with CIS cells shares characteristic similarities with the expression in foetal gonocytes.

16 January 2008 in International Journal of Andrology
Verified
Journal Article
Closed access
PDF file
SSSi Brask Sonne
Si Brask Sonne
DKDavid Møbjerg Kristensen
David Møbjerg Kristensen
GNGuy Novotny
Guy Novotny
IOInge Ahlmann Olesen
Inge Ahlmann Olesen
JNJohn E. Nielsen
John E. Nielsen
HLHenrik Leffers
Henrik Leffers

14 January 2014 in Islets
Verified
Journal Article
Closed access
MBMarie Balslev Backe
Marie Balslev Backe
GNGuy Novotny
Guy Novotny
DCDan Ploug Christensen
Dan Ploug Christensen
LGLars Groth Grunnet
Lars Groth Grunnet
TMThomas Mandrup-Poulsen
Thomas Mandrup-Poulsen
Aim: An insufficient functional β-cell mass is a prerequisite to develop diabetes. Thus, means to protect or restore β-cell mass are important goals in diabetes research. Inflammation and proinflammatory cytokines play important roles in β-cell dysfunction and death, and recent data show that 2 miRNAs, miR-21 and miR-34a, may be involved in mediating cytokine-induced β-cell dysfunction. Therefore, manipulation of miR-21 and miR-34a levels may potentially be beneficial to β cells. To study the effect of long-term alterations of miR-21 or miR-34a levels upon net β-cell number, we stably overexpressed miR-21 and knocked down miR-34a, and investigated essential cellular processes. Materials and Methods: miRNA expression was manipulated using Lentiviral transduction of the β-cell line INS-1. Stable cell lines were generated, and cell death, NO synthesis, proliferation, and total cell number were monitored in the absence or presence of cytokines. Results: Overexpression of miR-21 decreased net β-cell number i...

1 June 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
EFEven Fjære
Even Fjære
UAUlrike L. Aune
Ulrike L. Aune
KRKristin Røen
Kristin Røen
AKAlison H. Keenan
Alison H. Keenan
TMTao Ma
Tao Ma
LMLise Madsen
Lise Madsen
Chronic low grade inflammation is closely linked to obesity-associated insulin resistance. To examine how administration of the anti-inflammatory compound indomethacin, a general cyclooxygenase inhibitor, affected obesity development and insulin sensitivity, we fed obesity-prone male C57BL/6J mice a high fat/high sucrose (HF/HS) diet or a regular diet supplemented or not with indomethacin (±INDO) for 7 weeks. Development of obesity, insulin resistance, and glucose intolerance was monitored, and the effect of indomethacin on glucose-stimulated insulin secretion (GSIS) was measured in vivo and in vitro using MIN6 β-cells. We found that supplementation with indomethacin prevented HF/HS-induced obesity and diet-induced changes in systemic insulin sensitivity. Thus, HF/HS+INDO-fed mice remained insulin-sensitive. However, mice fed HF/HS+INDO exhibited pronounced glucose intolerance. Hepatic glucose output was significantly increased. Indomethacin had no effect on adipose tissue mass, glucose tolerance, or GSIS when included in a regular diet. Indomethacin administration to obese mice did not reduce adipose tissue mass, and the compensatory increase in GSIS observed in obese mice was not affected by treatment with indomethacin. We demonstrate that indomethacin did not inhibit GSIS per se, but activation of GPR40 in the presence of indomethacin inhibited glucose-dependent insulin secretion in MIN6 cells. We conclude that constitutive high hepatic glucose output combined with impaired GSIS in response to activation of GPR40-dependent signaling in the HF/HS+INDO-fed mice contributed to the impaired glucose clearance during a glucose challenge and that the resulting lower levels of plasma insulin prevented the obesogenic action of the HF/HS diet.